BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis (AD).

INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended September 30, 2020.

CONMED Corporation announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies Virtual London Healthcare Conference at 12:25 p.m. ET on Wednesday, November 18, 2020.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the quarter ended September 30, 2020, and provided a corporate update.

TherapeuticsMD, Inc. announced an underwritten public offering of its common stock.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced entrance into an equity line of credit financing agreement with current shareholder Energy Capital, LLC for up to $12.0 million.

Reported positive topline data from pivotal Phase 3 Marigold Study of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) Awarded five-year cost-sharing contract with Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for refractory status epilepticus (RSE)

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will be an invited speaker at the 3 rd Annual Neuropsychiatric Drug Development Summit being held virtually November 10-12, 2020. Details of Dr. Lederman’s presentation are as follows: Event 3 rd Annual Neuropsychiat

Celcuity Inc., a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the third quarter ended September 30, 2020 and summarized recent business progress.